The World Health Organization (WHO) declared tuberculosis (TB) a global emergensy in recognition of its growing importance as public health problem. In response to this situation WHO in 1990 was developed new strategy and framework for effective TB control, wich was called „DOTS“. The aims of treatment of TB are: to cure the pation of TB, to prevent death from active TB or its late effects, to prevent relapse of TB, to decrease transmission of TB to others, and to prevent
the development of acqured drug resistance. Antituberculosis drugs (ATD) are antibiotics and synthetic drugs used in the
treatment of tuberculosis and other deases caused by microorganisms of the genus Mycobacterium. The essential ATD are:
isoniazid (H), rifampicin (R), pyrazinamid (Z), streptomycin (S), ethambutol (E), and thioacetazone (T). The reserve ATD
are: amikacin (Am), kanamycin (Km), capreomycin (Cm), ciprofloxacin (Cx), ofloksacin (O), cycloserine (Cs), ethionamide (Et), protionamide (Pt), and p-aminosalycilic acid (PAS). The regimen recommended for each patient depends on the
diagnostic category for each patient. There are several possible regimens. ATB treatment regimens consists of two phases:
an initial phase and a continuation phase